7 research outputs found
Reactive hyperemia is associated with adverse clinical outcomes in heart failure
© 2016 Elsevier Inc. All rights reserved. Introduction Impaired endothelial function, as assessed by brachial artery flow-mediated dilation (FMD), is an established risk factor for cardiovascular events. FMD is impaired in heart failure (HF) patients, but less is known about hyperemic brachial artery flow. We investigated the relationship between FMD and hyperemic flow with adverse clinical outcomes in HF patients. Methods Brachial artery FMD and hyperemic flow were assessed in 156 patients (70.5 % Male; 45.5% Caucasian; mean age (± SD) = 56.2 (±12.4) years) with HF and reduced left ventricular ejection fraction (LVEF). Cox proportional hazard models were used to assess the potential explanatory association of FMD and hyperemic flow with the composite outcome of death or cardiovascular hospitalization over a median 5-year follow-up period. Results Both FMD and hyperemic flow were negatively correlated with age, but unrelated to sex, race, body mass index, LVEF or N-terminal pro-B-Type natriuretic peptide (NT-ProBNP). Reduced hyperemic flow, but not FMD, was associated with an increased risk of death or cardiac hospitalization after controlling for traditional risk factors. Conclusion The association of reduced hyperemic flow with increased risk of adverse clinical outcomes suggests that micro-vascular function may be an important prognostic marker in patients with HF
Community burden and prognostic impact of reduced kidney function among patients hospitalized with acute decompensated heart failure: The Atherosclerosis Risk in Communities (ARIC) Study Community Surveillance - Fig 1
<p>1-year survival according to eGFR categories based on the worst (A) and last (B) serum creatinine after ADHF admission.</p
Adjusted odds ratio of 1-year mortality according to eGFR categories with additional adjustment for potential mediators (sodium and hemoglobin) and another kidney measure, blood urea nitrogen (BUN).
<p>Adjusted odds ratio of 1-year mortality according to eGFR categories with additional adjustment for potential mediators (sodium and hemoglobin) and another kidney measure, blood urea nitrogen (BUN).</p
Adjusted odds ratio of mortality outcomes according to BUN categories.
<p>Adjusted odds ratio of mortality outcomes according to BUN categories.</p
Adjusted odds ratio of mortality outcomes according to eGFR categories.
<p>Adjusted odds ratio of mortality outcomes according to eGFR categories.</p
Adjusted odds ratio of 1-year mortality according to eGFR categories based on last serum creatinine in demographic subgroups.
<p>Models adjusted for primary covariates: age, race, gender, health insurance, diabetes, hypertension, smoke, history of coronary heart disease, heart failure type (preserved vs. reduced ejection fraction), and chronic obstructive pulmonary disease.</p
Baseline characteristics according to eGFR categories based on the last serum creatinine levels during ADHF hospitalization.
<p>Baseline characteristics according to eGFR categories based on the last serum creatinine levels during ADHF hospitalization.</p